The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy

Last updated: August 7, 2024
Sponsor: Neuronostics Ltd
Overall Status: Active - Recruiting

Phase

N/A

Condition

Epilepsy

Treatment

BioEP

Clinical Study ID

NCT06097195
NNBioEP002
  • Ages > 18
  • All Genders

Study Summary

Neuronostics plan a prospective multisite trial to determine the clinical utility of BioEP in the context of diagnostic decision making. Neuronostics will use findings from the trial to improve user experience of the Neuronostics platform (the tool which clinicians use to obtain a BioEP score from EEG and the aligned report). The data coming from the trial will also enable Neuronostics to iterate the BioEP algorithms and so improve future performance.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult (age 18 and above) presenting with first suspected seizure(s)

  • Able to give informed consent

  • Patient receives EEG following clinicians' decision to refer for an EEG based onclinical history and seizure description taken during first seizure clinic.

Exclusion

Exclusion Criteria:

  • Participants unable to tolerate an EEG test so no EEG data were gathered

  • Participants with a known hepatic/renal encephalopathy

  • Participants that upon history taking have a clear clinical diagnosis of a physicalcondition other than epilepsy (e.g. vasovagal syncope)

Study Design

Total Participants: 559
Treatment Group(s): 1
Primary Treatment: BioEP
Phase:
Study Start date:
May 21, 2024
Estimated Completion Date:
July 01, 2027

Study Description

Neuronostics will conduct a two-arm randomised control trial with two groups: (i) Usual Care, (ii) Usual Care + BioEP score and report. In this context, usual care involves clinical/ patient history, eye-witness accounts and any standard tests ordered (electroencephalogram (EEG), Magnetic Resonance Imaging (MRI), blood tests etc.). Investigators will recruit adults attending first seizure clinics where there is a suspicion that epilepsy is the causing symptoms and so a first EEG is recommended. Participants will be sourced from 10 sites. The trial duration will be 1 year recruitment, and 2 year follow up period.

Randomisation: Consenting individual patients will be randomly assigned to either Usual Care or Usual Care + BioEP in a 1:1 ratio. Randomisation will be stratified by centre, with eligible and consenting participants allocated in random blocks. The allocation schedule will be generated by the trial statistician, and concealed from the clinicians assessing eligibility and recruiting patients.

Connect with a study center

  • Royal Cornwall Hospitals Trust

    Truro,
    United Kingdom

    Active - Recruiting

  • The Royal Wolverhampton NHS Trust

    Wolverhampton,
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.